Has this been posted? From a friend of MSB...
Re" Cleveland Clinic Crohn's trial...
Anyway, results very good in the P1B/2A trial. Of the 23 patients, 18 received the MSCs and 5 were controls. No adverse events from the MSC treatment.
83% of the treatment group had complete clinical and radiographic healing (15/18 patients) versus only 40% of the controls (2/5 patients).
Disease activity index, incontinence and vanassche scores all significantly decreased in treatment patients at 6 months vs none decreased in the control group.
Conclusion: Bone marrow-derived MSCs offer a safe and effective alternative treatment approach for severe peri*&^% fistulizing Crohn's disease.
Early days, and a couple of P3 trials are yet to be done, but this could be another potential source of a strategic partnership .
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-17290
-
- There are more pages in this discussion • 623 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
0.020(2.11%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
94.5¢ | 98.0¢ | 93.5¢ | $3.680M | 3.810M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 149921 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 60000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 149921 | 0.965 |
5 | 66704 | 0.960 |
5 | 98366 | 0.955 |
4 | 43570 | 0.950 |
4 | 130698 | 0.945 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 60000 | 1 |
0.980 | 224951 | 2 |
0.985 | 227011 | 7 |
0.990 | 214282 | 8 |
0.995 | 68432 | 3 |
Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |